{
    "output": [
        [
            "Veracyte",
            "COMP",
            "Reiterate",
            "2017 Revenue and Cash Burn Guidance",
            "ECON_INDICATOR"
        ],
        [
            "Veracyte",
            "COMP",
            "Advance",
            "Genomic Tests",
            "PRODUCT"
        ],
        [
            "Veracyte",
            "COMP",
            "Operate_In",
            "Genomic Diagnostics Industry",
            "SECTOR"
        ],
        [
            "Veracyte",
            "COMP",
            "Consolidate",
            "Clinical, Medical and R&D Functions",
            "CONCEPT"
        ],
        [
            "Veracyte",
            "COMP",
            "Headed_By",
            "Giulia C. Kennedy",
            "PERSON"
        ],
        [
            "Veracyte",
            "COMP",
            "Expand",
            "Sales Team",
            "SECTOR"
        ],
        [
            "Veracyte",
            "COMP",
            "Appoint",
            "Jessica Meng",
            "PERSON"
        ],
        [
            "Jessica Meng",
            "PERSON",
            "Come_From",
            "Genentech",
            "COMP"
        ],
        [
            "Genentech",
            "COMP",
            "Lead",
            "Avastin",
            "PRODUCT"
        ],
        [
            "Veracyte",
            "COMP",
            "Believe",
            "Strategic Realignments and New Appointments",
            "CONCEPT"
        ],
        [
            "Veracyte",
            "COMP",
            "Enable",
            "Actively Manage Business Dynamics",
            "CONCEPT"
        ],
        [
            "Veracyte",
            "COMP",
            "Focus",
            "Investments",
            "CONCEPT"
        ],
        [
            "Veracyte",
            "COMP",
            "Optimize",
            "Commercial Opportunities",
            "CONCEPT"
        ],
        [
            "Veracyte",
            "COMP",
            "Reiterate",
            "2017 Annual Revenue Guidance",
            "ECON_INDICATOR"
        ],
        [
            "Veracyte",
            "COMP",
            "Reiterate",
            "2017 Annual Cash Burn Guidance",
            "ECON_INDICATOR"
        ],
        [
            "Veracyte",
            "COMP",
            "Expect",
            "Fourth Quarter 2017 Reported Genomic Test Volume",
            "ECON_INDICATOR"
        ],
        [
            "Afirma",
            "PRODUCT",
            "Improve",
            "Diagnosis of Thyroid Cancer",
            "CONCEPT"
        ],
        [
            "Percepta",
            "PRODUCT",
            "Improve",
            "Diagnosis of Lung Cancer",
            "CONCEPT"
        ],
        [
            "Envisia",
            "PRODUCT",
            "Positioned",
            "Gain Medicare Coverage",
            "CONCEPT"
        ],
        [
            "Veracyte",
            "COMP",
            "Provide",
            "Genomic Diagnostics",
            "PRODUCT"
        ],
        [
            "Veracyte",
            "COMP",
            "Transform",
            "Diagnosis of Thyroid Cancer, Lung Cancer and Idiopathic Pulmonary Fibrosis",
            "CONCEPT"
        ],
        [
            "Veracyte",
            "COMP",
            "Target",
            "$2 Billion Market Opportunity",
            "ECON_INDICATOR"
        ],
        [
            "Veracyte",
            "COMP",
            "Based_In",
            "South San Francisco, California",
            "GPE"
        ]
    ]
}